IvoLoC Trial: A Phase II Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT07229417
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Metastatic Endocrine Refractory
  • Triple Negative Invasive Lobular Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

To learn if ivonescimab can help to control endocrine-refractory HR+ HER2- and/or TN mILC.

Key Dates

Start date
Oct 22, 2025
Status verified
Jun 2026
Primary completion
Sep 30, 2027
Completion
Sep 30, 2029

Study Design

Enrollment
29 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Phase II: Treatment with Ivonescimab
    Participants found to be eligible to take part in this study, you will receive ivonescimab by vein over about 60 minutes on Day 1 of each 21-day cycle.

Primary Outcome Measure

Safety and adverse events (AEs) [ Time Frame: an average of 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
MD Anderson Cancer CenterHoustonTexas77030
Jason Mouabbi, MD
[email protected]
713-792-7676
Jason Mouabbi, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

By research site
MD Anderson Cancer Center· Houston, TX